Kanaph Therapeutics
Yongsan
About Kanaph Therapeutics
Kanaph Therapeutics is a biotech with activities that range from drug discovery to early-stage clinical trials. It is dedicated to developing next-generation therapeutics for oncology and autoimmune diseases. Their oncology pipeline includes bi-specific antibodies and small molecules that have a greatly enhanced immuno-stimulatory activity in the tumor microenvironment for efficient tumor eradication. The company's autoimmune disease pipeline is composed of bispecific Fc-fusions that inhibit the alternative complement pathway while inhibiting angiogenesis and downstream complement activation as well.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $44.8M
- Funding stage: Late Stage Venture
- Last round: Series C (Dec 2023)
- Website: kanaphtx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Life Science, Oncology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/kanaph-therapeutics-101653 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.